Sign in
Not yet taking people in FrancePhase 4

Compares anti-TNF, vedolizumab and tofacitinib for ulcerative colitis and blood vessel health

Compares anti-TNF, vedolizumab and tofacitinib on blood vessels in adults with ulcerative colitis.

Key facts

Who runs it
Centre Hospitalier Universitaire Amiens Picardie
Where
Amiens Cedex 1, FranceSee the site
Registry title
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Status
Not yet recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
3 Jun 2021
Planned end
2 Jun 2026
Type of study
Interventional
Record updated
10 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ulcerative colitis who are about to start infliximab, adalimumab, golimumab, vedolizumab or tofacitinib. It looks at how these drugs affect artery thickness.

Age
Older than 18 years
Sex
Men and women
Disease stage
Ulcerative colitis present for at least 6 months
Earlier treatment
Must be starting treatment with infliximab, adalimumab, golimumab, vedolizumab or tofacitinib. Blood pressure, antiplatelet or cholesterol drugs must have a stable dose in the 3 months before and during the study.

Main reasons for not taking part

  • Heart attack or stroke
  • Diabetes
  • Pregnant or breastfeeding women
  • Not covered by French national health insurance
  • Under 18 years old, or deprived of liberty or under guardianship

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Ulcerative colitis evolving for at least 6 months
  • Patient older than 18 years
  • Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib
  • Patient covered by French national health insurance
  • Written informed consent

Who cannot take part

  • Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period
  • Patients with a cardiovascular event such as myocardial infarction and stroke
  • Diabetic patient
  • Pregnant women or breastfeeding
  • Minor
  • Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)

Where in France

  • Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting

About the trial

What the trial wants to find out

To compare the CIMT after 3 months of therapy in ulcerative colitis in patients treated by anti-TNF, vedolizumab, and tofacitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Plain-language title
Compares anti-TNF, vedolizumab and tofacitinib for ulcerative colitis and blood vessel healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
10 September 2024